STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Passage Bio (NASDAQ: PASG) announced that Will Chou, M.D., president and CEO, will participate in a fireside chat at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 9:30 a.m. ET in Boston.

A live webcast will be available on the company’s Investors & News website at investors.passagebio.com, and a replay will be available for 90 days following the event.

Passage Bio (NASDAQ: PASG) ha annunciato che Will Chou, M.D., presidente e CEO, parteciperà a una chiacchierata informale durante la Guggenheim Securities 2nd Annual Healthcare Innovation Conference il mercoledì 12 novembre 2025 alle ore 9:30 ET a Boston.

Una webcast in diretta sarà disponibile sul sito Investors & News della società all'indirizzo investors.passagebio.com, e una riproduzione sarà disponibile per 90 giorni dopo l'evento.

Passage Bio (NASDAQ: PASG) anunció que Will Chou, M.D., presidente y director ejecutivo, participará en una charla junto a la chimenea durante la Conferencia Anual de Innovación en Atención Médica de Guggenheim Securities 2ª edición el miércoles 12 de noviembre de 2025 a las 9:30 a.m. ET en Boston.

Un webcast en vivo estará disponible en el sitio de Investors & News de la empresa en investors.passagebio.com, y una retransmisión estará disponible por 90 días tras el evento.

Passage Bio (NASDAQ: PASG)는 Will Chou, M.D., 사장 겸 CEO가 보스턴에서 열리는 Guggenheim Securities 2nd Annual Healthcare Innovation Conference에서 수요일 2025년 11월 12일 오전 9시 30분 ET에 fireside chat에 참여할 것이라고 발표했습니다.

라이브 웹캐스트는 회사의 Investors & News 웹사이트의 investors.passagebio.com에서 이용 가능하며, 이벤트 후 90일리플레이가 제공됩니다.

Passage Bio (NASDAQ : PASG) a annoncé que Will Chou, M.D., président et directeur général, participera à une conversation informelle lors de la Guggenheim Securities 2nd Annual Healthcare Innovation Conference le mercredi 12 novembre 2025 à 9 h 30 HE à Boston.

Un webcast en direct sera disponible sur le site Investors & News de l'entreprise à l'adresse investors.passagebio.com, et un replay sera disponible pendant 90 jours après l'événement.

Passage Bio (NASDAQ: PASG) gab bekannt, dass Will Chou, M.D., Präsident und CEO, an einem Fireside-Chat bei der Guggenheim Securities 2nd Annual Healthcare Innovation Conference am Mittwoch, 12. November 2025 um 9:30 Uhr EST in Boston teilnehmen wird.

Ein Live-Webcast wird auf der Website der Investors & News des Unternehmens unter investors.passagebio.com verfügbar sein, und eine Wiederholung wird 90 Tage nach der Veranstaltung verfügbar sein.

شركة Passage Bio (يناNASDAQ: PASG) أعلنت أن ويل تشو، دكتور في الطب، رئيس ومدير تنفيذي، سيشارك في جلسة fireside chat في المؤتمر السنوي الثاني للابتكار في الرعاية الصحية من Guggenheim Securities يوم الأربعاء 12 نوفمبر 2025 الساعة 9:30 صباحًا بتوقيت شرق الولايات المتحدة في بوسطن.

سيكون هناك بث مباشر عبر موقع Investors & News للشركة على العنوان investors.passagebio.com، وسيكون هناك إعادة عرض لمدة 90 يومًا بعد الحدث.

Positive
  • None.
Negative
  • None.

PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will participate in a fireside chat during the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 9:30 a.m. ET in Boston, MA.

A live webcast of the event will be available on the Investors & News section of Passage Bio’s website at investors.passagebio.com. A replay of the event will be available for 90 days following the event.

About Passage Bio

Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression. 

To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: passagebio.com.

For further information, please contact:

Investors:
Stuart Henderson
Passage Bio
shenderson@passagebio.com

Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
mikebeyer@sambrown.com


FAQ

When will Passage Bio (PASG) present at the Guggenheim Healthcare Innovation Conference?

Will Chou will speak on Wednesday, November 12, 2025 at 9:30 a.m. ET.

How can investors watch the Passage Bio (PASG) fireside chat webcast on November 12, 2025?

The live webcast will be available on Passage Bio's Investors & News page at investors.passagebio.com.

Will there be a replay of the Passage Bio (PASG) presentation from the conference?

Yes. A replay will be available for 90 days after the event on the investor site.

Who from Passage Bio (PASG) will participate in the Guggenheim conference fireside chat?

Will Chou, M.D., president and chief executive officer, will participate in the fireside chat.

Where is the Guggenheim Securities 2nd Annual Healthcare Innovation Conference taking place on November 12, 2025?

The conference will be held in Boston, MA.
Passage Bio, Inc.

NASDAQ:PASG

PASG Rankings

PASG Latest News

PASG Latest SEC Filings

PASG Stock Data

20.69M
3.04M
0.21%
54.5%
2.63%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
PHILADELPHIA